This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

This study has been terminated.
(Withdrawn due to lack of enrollment.)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: August 14, 2007
Last updated: July 9, 2013
Last verified: March 2008

RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Evaluating blood or tissue samples from patients with cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and predict how well patients will respond to combination chemotherapy.

PURPOSE: This phase II trial is studying gene expression profiling to see how well it works in predicting response to treatment in patients with invasive bladder cancer receiving methotrexate, vinblastine, doxorubicin, and cisplatin.

Condition Intervention Phase
Bladder Cancer Drug: cisplatin Drug: doxorubicin hydrochloride Drug: methotrexate Drug: vinblastine Genetic: gene expression profiling Procedure: neoadjuvant therapy Phase 2

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial Concerning Gene Expression Profiling to Predict the Chemosensitivity of Invasive Bladder Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Detection of genes associated with sensitivity to the chemotherapy in tumor size reduction of original bladder tumor

Secondary Outcome Measures:
  • Safety
  • Overall survival rate
  • Size reduction of metastatic lesion

Estimated Enrollment: 100
Study Start Date: July 2007
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Detailed Description:



  • Analyze the correlation between gene expression profile and the effect of chemotherapy and detect the significant cluster of genes useful to predict chemosensitivity.
  • Confirm the reduction in original tumor size in patients with invasive bladder cancer treated with methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin.


  • Determine the safety of this regimen in these patients.
  • Determine the overall survival rate in patients treated with this regimen.
  • Assess the reduction in size of metastatic lesions in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive methotrexate on days 1, 15, and 22, vinblastine on days 2, 15, and 22, doxorubicin hydrochloride and cisplatin on day 2. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patient samples will be collected for gene expression profiling.

After completion of study treatment, patients are followed for 3 years.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of invasive bladder cancer
  • Must be confirmed by chest and abdominal CT scan OR pelvic MRI scan and transurethral biopsy (with definitive muscle invasion > T2) within 4 weeks prior to registration


  • ECOG performance status 0-1
  • WBC ≥ 3,000/mm^3
  • Neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Total bilirubin ≤ 1.5 mg/dL
  • Serum creatinine ≤ 1.5 mg/dL
  • AST and ALT ≤ 2.5 x upper limit of normal
  • Not pregnant
  • No liver cirrhosis
  • No ischemic cardiovascular disease or arrhythmia for which treatment is necessary
  • No cardiac infarction within the past 6 months
  • No interstitial pneumonia, pulmonary fibrosis, or any other diseases by which oxygen inhalation therapy is needed
  • No active cancerous lesion other than upper urinary tract tumor
  • No high fever or any other infectious symptom
  • No uncontrolled hypertension or diabetes mellitus


  • No prior systemic chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00516750

Nagoya University Hospital
Nagoya, Aichi, Japan, 466-8560
Shiga Medical Center for Adults
Moriyama, Shiga, Japan, 524-8524
Kyoto University Hospital
Kyoto, Japan, 606-8507
National Hospital Organization - Kyoto Medical Center
Kyoto, Japan, 612-0861
Osaka Red Cross Hospital
Osaka, Japan, 543-8555
Sponsors and Collaborators
Kyoto University
Study Chair: Osamu Ogawa, MD, PhD Kyoto University
  More Information Identifier: NCT00516750     History of Changes
Other Study ID Numbers: TRIC-UHA-GU-03-01
CDR0000561303 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: August 14, 2007
Last Updated: July 9, 2013

Keywords provided by National Cancer Institute (NCI):
recurrent bladder cancer
stage II bladder cancer
stage III bladder cancer
stage IV bladder cancer

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Liposomal doxorubicin
Antineoplastic Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on September 19, 2017